Triple‐negative breast cancer (TNBC) is an aggressive form of breast cancer with limited
treatment modalities and poor prognosis. Metabolic reprogramming in cancer is considered …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
deaths in the US. Cancer-associated cachexia is present in up to 80% of PDAC patients and …

Metabolic reprogramming is an emerging hallmark of cancer cells, in which cancer cells
exhibit distinct metabolic phenotypes to fuel their proliferation and progression. The …

Oncogenic signaling reprograms cancer cell metabolism to augment the production of
glycolytic metabolites in favor of tumor growth. The ability of cancer cells to evade …

Background Among breast cancers, the triple-negative breast cancer (TNBC) subtype has
the worst prognosis with no approved targeted therapies and only standard chemotherapy …

Triple-negative breast cancers (TNBCs) are aggressive and lack targeted therapies.
Understanding how nutrients are used in TNBCs may provide new targets for therapeutic …

Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of
metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the …

Background Chemoresistance is the major cause of therapeutic failure in triple negative
breast cancer (TNBC). In this work, we investigated the molecular mechanism for the …

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with very
limited therapeutic options. We have recently shown that the combined inhibition of EGFR …

Triple-negative breast cancer (TNBC) exhibits innate resistance to the EGFR inhibition
despite high level expression of EGFR. Recently, we found that the proliferation of basal-like …